Compare Nuwellis Inc (NUWE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs BIO-TECHNE Corp — how do they compare? Nuwellis Inc trades at $2.84 (market cap $1.09M), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 10238.5× Nuwellis Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | TECH | |
|---|---|---|
Market Cap | $1.09M | $11.16B |
Sector | Technology | Health |
52-Week High | $527.46 | $72.12 |
52-Week Low | $2.80 | $43.31 |
Enterprise Value | -$722.58K | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
